Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

Background: In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain health...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Moorkens, Evelien, Jonker-Exler, Clara, Huys, Isabelle, Declerck, Paul, Simoens, Steven, Vulto, Arnold G.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2016
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4925708/
https://ncbi.nlm.nih.gov/pubmed/27445826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00193
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars